We observed several key features in ‘tumour‐driving’ GBM patients: (1) mutual exclusivity between prognostic factors TP53 and EGFR; and (2) IDH1 mutations co‐occurring with TP53, which account for the protective role of IDH1 in TP53 mutant patients. This evidence concerns the gene EGFR and glioblastoma.